SIRIUS XM Radio Inc. Message Board

* Says FDA seeks more data to evaluate vaccine's safety

* Says FDA willing to discuss restricted approval

Feb 25 (Reuters) - U.S. health regulators denied approval for Dynavax Technologies Inc's adult hepatitis B vaccine pending additional data to evaluate its safety, potentially delaying the U.S. market entry of the company's first promising product.

The U.S. Food and Drug Administration, however, indicated it was willing to have discussions for a more restricted use of the vaccine Heplisav, Dynavax said.

The company also said the FDA continues to express concern that novel adjuvants that Heplisav contains may cause rare autoimmune events.

Adjuvants are added to vaccines to improve their ability to trigger an immune response, but they carry the risk of causing several potentially fatal adverse reactions.

Advisors to the U.S. FDA had flagged safety concerns on Heplisav in November, even as they voted unanimously to support the efficacy of the vaccine.

"Furthermore, the FDA requested additional data ... clarifying information on the manufacturing controls and facilities related to the assurance of the quality of the commercial product," Dynavax said in a statement.

The company said it expects to meet with the FDA within six weeks to discuss the steps required for Heplisav's approval.

The rejection brings into question the future Dynavax, which has no drugs on the market. The company has been generating revenue so far through its research and development alliances.

An estimated 3.5 million to 5.3 million people are living with viral hepatitis in the United States, and vaccination is crucial as it prevents progression of the infection, which is the leading cause of liver cancer.

Dynavax pitched Heplisav for use in patients between 18 and 70 years of age. The company estimates the global market for adult hepatitis B vaccines at about $700 million annually.

The hepatitis B market is currently dominated by GlaxoSmithKline Plc's Engerix B and Merck & Co's Recombivax HB vaccines. Does this method have anything to do with ADXS's method by any chance?

} NEOM {NeoMedia Technologies TREMENDOUS BUYING OPPORTUNITY Chasing Apple? Microsoft's SIGNS NeoMedia } NEOM { QR Code Patent Deal Puts More Focus On Geometric Boxes NeoMedia grants @kraftfoods worldwide rights to license its patent portfolio QR Code Patent Deal Puts More Focus On Geometric Boxes NeoMedia grants @kraftfoods worldwide rights to license its patent portfolio NEOMEDIA TECHOLOGIES SURVIVED THROUGH THE ECONOMIC RECESSIONS OVER the past years since 1998.

Panic has set in now that so many people are bleeding money in their AAPL investment. Notice how everyone lives the Z10 and thinks it is a great experience, fastest phone, etc. The only thing they seem to use as a reason it will fail is that neither Instagram or Netflux available. That's it? I don't mind using the fastest browser to get Netflix. Instagram? Zzzzzz....

Sentiment: Strong Buy

coulda got in at sub 2.50
the recall was voluntary downgrades premature

Interesting

If you are looking for info about the stock market, then you can see this.
Link:- microcapwatcher(DOT)biz/VHC

Sentiment: Strong Buy

lol losers